“We have long worked on expanding the genetic code of cells to endow them with new capabilities to enable research, biotechnology and medicine in different areas...This novel synthetic biology platform solves many of the obstacles that stood in the way of upgrading proteins with new chemistries, as exemplified by more capable instant biosensors, and is poised to impact many biomedical areas," says Core Faculty member George Church regarding a new technology developed in collaboration with Core Faculty member Jim Collins and the The University of Edinburgh. Learn more about it in this story from Semiconductor Digest. #SyntheticBiology #Biosensors https://lnkd.in/eTjP86Cf
Wyss Institute at Harvard University
Biotechnology Research
Boston, MA 57,612 followers
About us
At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.
- Website
-
http://wyss.harvard.edu
External link for Wyss Institute at Harvard University
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Nonprofit
- Specialties
- Robotics, Bioengineering, Microfluidics, Medicine, Materials Science, Medical Devices, Synthetic Biology, Cell biology, Tissue engineering, Cancer research, Molecular engineering, Organ Engineering, Genome Editing, Molecular Robotics, and Immunomaterials
Locations
-
Primary
201 Brookline Ave.
Boston, MA 02215, US
Employees at Wyss Institute at Harvard University
-
Gangadhar Jogikalmath
Co-Founder Return To Vendor (RTV)
-
Ayis Antoniou
Entrepreneur/mentor/experienced, impactful, innovative leader/strategic advisor looking to connect with early-stage companies in bio-tech
-
James Gorman, M.D., Ph.D.
-
Samir Mitragotri
Professor @ Harvard University | Hiller Professor of Bioengineering | Hansjorg Wyss Professor of Biologically Inspired Engineering | Wyss Institute
Updates
-
Catalytic converters are the most widely used kind of air pollution control device, but they're expensive and inefficient. This means they aren't always replaced as often as they should be. So, Wyss researchers developed a butterfly-inspired coating for catalytic converters that dramatically lowers the cost of cleaning air. This technology is available for licensing. #Sustainability #AirPollution #CleanAir https://lnkd.in/gEuyUxmB
Catalytic Materials: Cheaper, Better Air Purification for a Healthier World
https://wyss.harvard.edu
-
Researchers at the Wyss developed Crisscross Nanoseed Detection, an enzyme-free DNA nanotechnology for the rapid, ultrasensitive, and low-cost detection of infectious disease biomarkers with broad accessibility in point-of-care settings. #Diagnostics #DNA #Nanotechnology https://lnkd.in/eek_3UyY
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
https://wyss.harvard.edu
-
The lymph system is critical for proper immune function, and inflammation can cause its vessels to close, leading to a number of diseases. Ropirio Therapeutics, Inc., a new Wyss startup, launched to commercialize the first drug that specifically targets and reopens lymphatic vessels. Read more in this story from the Boston Business Journal. #Startup #Entrepreneurship #Therapeutics https://lnkd.in/exTcWgFk
Petri Dish: A big week for the Wyss; bone adhesive gets NIH funding - Boston Business Journal
bizjournals.com
-
This story from The Scientist explores how various researchers, including Wyss postdoc Elizabeth Hann, are exploring how unicellular aquatic organisms could help humanity exist more sustainably. #Sustainability #Microorganisms #SyntheticBiology https://lnkd.in/eV86dvyc
Better Living Through Algae Biotechnology
the-scientist.com
-
Immune-modulating biomaterial technology developed in David Mooney’s group has been licensed to the Wyss startup Attivare Therapeutics, which will first use it to develop new types of immunotherapies for patients with solid tumors and heme malignancies who don’t respond to existing immunotherapies yet. #Immunotherapy #Startups #CancerTreatment https://lnkd.in/gf8zjRJM
-
Today we're highlighting Visiting Researcher Carmen Escobedo-Lucea who comes from Teruel, Spain. She explains that she deeply values incorporating traditions from her culture into her daily life. #HispanicHeritageMonth
-
Congratulations to Wyss Lumineer Jocelyn (Josie) Kishi, PhD on being named one of MIT Technology Review's 35 Innovators Under 35! Josie left the Wyss with startup Digital Biology, Inc., a precision measurement platform to streamline design of next-generation therapies. #Biotech #Startups https://lnkd.in/eD34tHma
Josie Kishi
technologyreview.com
-
It's #InternationalPodcastDay! We want to give a shoutout to one of our favorites, Innovate and Elevate. In each episode, host Sharon Kedar, CFA speaks to doctors, scientists, or innovators about cutting-edge discoveries, many related to the grand challenge of women's health. Sharon is also Co-Founder and Partner at Northpond Ventures, a collaborator of the Wyss. What's your favorite podcast that's shining a light on an important topic? https://lnkd.in/eQ_ZXTKp #WomensHealth #Podcast
Innovate and Elevate Podcast
innovateandelevatepodcast.com
-
Researchers working on the Wyss’ Biostasis project have demonstrated that a non-addictive pain relief drug could be used to preserve cells and organs quickly and safely for transplantation, removing the need for static cold storage. The drug compound, named SNC80, can rapidly and reversibly slow biochemical and metabolic activities while preserving cell and tissue viability, which, in the future, could help ensure donor organs can be preserved safely for longer ahead of transplantation and slow the detrimental effects of tissue and organ trauma across a wide range of health emergencies. Megan Sperry #OrganDonorShortage #Therapeutics https://lnkd.in/gBp76sTK
“Suspended animation” drug could aid organ transplantation and survival from traumatic injury
https://wyss.harvard.edu